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Abstract Human face transplantation is now a clinical reality. The surgical techniques nec-
essary to perform these procedures have been used routinely in reconstructive microsurgery
for many years. From an immunological standpoint since face and hand contain mostly the
same tissues it is reasonable to assume that the same immunosuppressive regimen found to
be effective in human hand transplants should also work in face transplantation. It is the eth-
ical issues associated with the risks and benefits of performing facial transplantation that have
posed the greatest challenges leading up to performing this new procedure.
In this editorial, we will review some of the main events that have led to the recently per-
formed human face transplants, specifically focusing on the key ethical issues at the center of
this debate. We will discuss how the research and clinical experience in human hand transplan-
tation laid the foundation for performing face transplantation and describe the research and
the ethical guidelines upon which a team at the University of Louisville based their position
‘‘to move ahead’’ in spite of much criticism. Finally we will outline some of the key arguments
against face transplantation, and conclude with a discussion on what comes next now that the
first human face transplants have been performed.
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The apparent success of human hand transplantation in the
late 1990s laid the immunological and ethical groundwork for
performing human face transplants and led scientists and
physicians to consider the use of donor facial tissues for
reconstructing severe facial deformities. In December 2002,
the public became aware that face transplantation could
become a clinical reality when, at the annual meeting of the
British Association of Plastic Surgeons, British plastic surgeon
Peter Butler reported that he had been contacted by several
potential patients interested in receiving face transplants
(see Table 1).1 The media present at the event reported that
face transplant was indeed a clinical reality and speculated
that Mr. Butler’s team in the UK was racing a team in the US
to become the first to perform the procedure. This sparked
a media frenzy in the UK, causing James Partridge, the CEO
of the well recognized support organization for people with
a facial disfigurement, ‘‘Changing Faces,’’ to call on the
Royal College of Surgeons (RCS) to ‘‘create a moratorium
on further media coverage of the issue.’’ In response the
RCS formed a ‘‘Working Party on Face Transplantation’’
and in November 2003 issued a report that ‘‘.it would be un-
wise to proceed with human facial transplantation’’. In re-
sponse to the RCS report, a team at the University of
Louisville in the US published an editorial in this journal in
which they contested the RCS Working Party findings, writing
‘‘.the time has come to move facial transplantation re-
search into the clinical arena’’.2 This position sparked a great
deal of controversy, igniting a lively debate on the ethics of
face transplantation, which continues today.
Today, two years later, many events have transpired
including 2 highly publicized and widely debated human
face transplants, performed by teams in France3,4 and
China.5 In this editorial, we will chronicle some of the main
events that have led to these first human face transplants,
specifically focusing on the key ethical issues at the center
of this debate. In this manuscript, we will discuss:
e How hand transplantation led to face transplantation
e Research upon which the Louisville team’s statement
‘‘to move ahead’’ was based
e Louisville team’s ethical guidelines
e Current standing of the key arguments against face
transplantation, and
e Now that the first human face transplants have been
performed, what’s next?
A table is provided that lists in chronological order key
events and publications related to face transplantation,
including those above. In addition, a graph is presented to
illustrate the distribution of publications on the ethical,
immunological, and surgical aspects of face transplantation
from 2002 to 2006.
How hand transplantation led to face
transplantation
As shown in Table 1, a team of surgeons in Ecuador per-
formed the first human hand transplant in 1963. While, at
the time, the immunosuppressive medications the surgicalteam used (azathioprine (AZA) and hydrocortisone) were
proving to be effective in solid organ transplantation,
they did not prevent skin rejection. After 3 weeks the
hand rejected and had to be removed.6,7 The introduction
of cyclosporine A, in 1976 brought new attempts to trans-
plant hands in a primate model; and while limb survival
was demonstrated for up to 300 days in these experiments,
the skin component of the grafts was rejected early on and
had to be removed.8e10 These discouraging results caused
reconstructive surgeons to abandon further attempts to
transplant hands until the late 1990’s. Then experiments
in a swine model demonstrated that a new drug combina-
tion (tacrolimus/MMF/corticosteroid), used routinely at
the time in solid organ transplants, effectively prevented
‘‘skin’’ rejection with relatively low toxicity.11,12 Between
1998 and 2000 these findings led teams in Lyon (France),13
Louisville (USA),14 and Guangzhou (China)15 to, for the first
time, perform successful human hand transplants using this
drug combination. This success in animal research, fol-
lowed by the early success in human hand transplants,
strongly suggested that, from an immunological standpoint,
facial tissue transplantation also could be successful.
Research upon which the Louisville team’s
position ‘‘to move ahead’’ was based
The fact that the drug combination of tacrolimus/MMF/
Prednisone effectively suppressed skin rejection in human
hand transplants indicated that this long-standing ‘‘immu-
nological’’ barrier had been lowered, and this opened the
door to performing human face transplants. The surgical
techniques necessary to perform face transplants were well
established based on decades of advances in reconstructive
surgical techniques. Now, with the immunological obstacles
lowered, the only barriers standing in the way were ethical
and psychosocial in nature. To address these ethical and
psychosocial hurdles, members of the hand transplant team
at the University of Louisville recruited a number of
scientists and clinicians in the fields of body image and
patient adjustment psychology, psychiatry, bioethics, soci-
ology, and plastic, head and neck, ophthalmologic, and
transplant surgery. Parting from the position that the
surgical and immunological barriers had been largely over-
come the team focused its research on exploring the social
and ethical parameters involved in human face transplan-
tation. Early on it became apparent that there were not
just immunological similarities between hand and face
transplantation (due to the presence of skin tissue); there
were also many ethical and psychosocial parallels. These
primarily centered on the question of whether the benefits
of receiving one of these non-life-saving treatments justify
the risks posed by the life-long immunosuppression re-
quired to prevent rejection.
To address this question, the Louisville team adapted
and expanded a risk versus benefit research protocol
developed while preparing to perform clinical hand trans-
plants,16 and the team used it for exploring face transplan-
tation. They developed and validated an instrument
(Louisville Instrument For Transplantation, LIFT)17 to ob-
jectively assess the opinions of individuals with real-life ex-
periences in the ‘‘risks’’ and ‘‘benefits’’ of transplantation.
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Date Event Location Reference(s)
1963 1st human hand transplant followed by
rejection & removal 3 weeks post transplant
Guayaquil, Ecuador 6,7
1986e92 Introduction of Cyclosporine A, brought new
attempts to transplant hands in primate model.
These attempts prolonged survival but failed due




1994 Replantation of full facial tissues following
degloving accident
Ludhiana, India 69
1995e97 Experiments in swine CTA model demonstrate
tacrolimus/MMF/Prednisone immunosuppression
prevents ‘‘skin’’ rejection w/relatively low toxicity
Louisville, USA 11,12
1997 1st International Symposium on Composite Tissue
Allotransplantation
Louisville, USA 70
Sepe1998 2nd human hand transplant e 1st to survive >2
years
Lyon, France 13
1999e2006 23 hands transplanted in 17 individuals World-wide 41
2000 2nd International Symposium on Composite Tissue
Allotransplantation
Louisville, USA 71
June05 Documentary ‘‘Face Transplant’’ aired in US
(Discovery Health Channel) & UK (Channel 4)
72
Febe2001 1st hand transplant rejected & removed due to
non-compliance
London, UK 43
1996e2000 Relevant Publications Prior to 20026 12,14e16,69,73
2002 Ethics publications2 74,75
2002 Immunology publications1 76
2002 Surgical technique publications1 77
Dece2002 Mr. Peter Butler made presentation at British
Assoc. of Plastic Surgeons Meeting
London, UK 40
Nove2003 Public Debate, ‘‘Feasibility of Face Transplant’’
at London Science Museum
London, UK 22,78
Nove2003 Royal College of Surgeons Working Party report
on face transplantation released
London, UK 40
2003 Ethics publications3 79e81
2003 Immunology publications2 42,82
2003 Surgical technique publications3 83e85
2004 Louisville team response to RCS report Louisville, USA 2
2004 ‘‘Open Display & Professional Discussion’’ Louisville
team publishes Ethical Guidelines along side invited
commentaries & response
23e39
June2005 French Ethics Committee, releases position paper
on facial transplantation
Paris, France 86
2004 Ethics publications39 2,17,23e39,56,57,87e104
2004 Immunology publications3 105e107
2004 Surgical technique publications2 108,109
Sepe2004 Human cephalocervical skin flap & two ears
allotransplant performed
Nanjing, China 110
Octe2004 Team at the Cleveland Clinic in the US receives
Institutional Review Board approval to perform
human facial transplantation
Cleveland, US 111
2005 Ethics publications11 112e122
2005 Immunology publications2 123,124
2005 Surgical technique publications5 3,41,125e127
Nove2005 1st human face transplant performed Amiens, France 3
Dece2005 Mr. Peter Butler at The Royal Free Hospital receives
approval to perform human face transplants
London, UK 111,128
Jane2006 American Society of Reconstructive Microsurgery
(ASRM) & American Society for Plastic Surgery (ASPS)
release facial transplantation ‘‘Guiding Principles’’
129,130
(continued on next page)
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Date Event Location Reference(s)
Apre2006 2nd human face transplant performed Xi’an, China 5
JaneJune 2006 Ethics publications23 18e20,111,129e131,
133e147
JaneJune 2006 Immunology publications2 148,149
JaneJune 2006 Surgical technique publications8 4,19,62,150e154The focus of the LIFT was to assess the amount of risk
that individuals would be willing to accept to receive non-
life-saving, but quality-of-life improving transplants. These
transplants included full face, hemi-face, double hand, sin-
gle hand, larynx, foot and kidney. Using this instrument,
over 300 individuals with different life experiences were
surveyed. These samples included facially disfigured indi-
viduals (who could benefit from a face transplant), ampu-
tees (who could benefit from a hand transplant),
individuals with larynjectomies (who could benefit from
a larynx transplant), kidney transplant recipients (who
live with the risks of immunosuppression), plastic surgeons
(who treat patients with facial disfigurement), transplant
surgeons (who treat patients on immunosuppression) and
healthy volunteers (who have no direct experience with
the benefits or the risks of face transplantation).
Findings from these studies indicated that, regardless of
the group questioned, all would risk more for face and
hemi-face transplants than for any of the other procedures.
Of particular note was the fact that all groups would risk
significantly more for a face and hemi-face than even for
a kidney transplant, which is a standard treatment for
which there is no debate regarding risk versus benefit.18e21
Based on these research findings, previous immunolog-
ical research, their clinical hand transplant experience, and
the growing number of successful human hand transplants
world-wide, the Louisville team concluded that the time
had come to move facial transplantation research into the
clinical arena. This position was presented at a much
publicized ‘‘Public Debate on the Feasibility of Face Trans-
plantation’’, on November 19th, 2003, at the London
Museum, at the same time as the findings of the Royal
College of Surgeons (RCS) Working Party report on face
transplantation were released22 (see Table 1). Also present
at the public debate, were Peter Butler, James Partridge,
and several members of the RCS Working Party, including
its chair, Sir Peter Morris.
The Working Party’s report, released that day, con-
cluded that ‘‘.until there is further research and the
prospect of better control of complications it would be
unwise to proceed with human facial transplantation’’. The
report ended by welcoming comments on these findings. In
response to the RCS report the Louisville team published an
editorial in this journal in 2004 entitled ‘‘The Technical,
Immunological and Ethical Feasibility of Face Transplanta-
tion’’. That editorial contested the RCS Working Party
findings, arguing the alternate stance that: ‘‘In the case
of facial transplantation, particularly in psychological and
societal issues, we find ourselves in a position where we are
destined to remain uncertain about whether the benefits
will outweigh the risks (or vice versa) until we actually
perform the procedure in humans and follow theoutcomes’’. Therefore ‘‘.the time has come to move
facial transplantation research into the clinical arena.’’
Louisville teams’ ethical guidelines
In addition to the risk versus benefit research described
above, the Louisville team expanded a set of ethical
guidelines, developed in 1997 while preparing to perform
human hand transplants,16 to include face transplantation.
These guidelines were published in the American Journal of
Bioethics23 alongside commentaries24e38 and the Louisville
team’s response to the commentaries39 (see below) (see
Table 1). These ethical guidelines stipulate that 8 criteria
should be met before moving forward. Four of these criteria
had been proposed by Dr. Francis Moore in the late 1980’s for
introducing innovative procedures in transplant surgery2:
1) Scientific background in the innovation: The prepara-
tory scientific groundwork should have been laid
through laboratory and clinical research on the perti-
nent medications, technology, procedures, and ethical
issues. This preparatory work will have significantly re-
duced the risks of the proposed procedure.
2) Skill and experience of the team: The surgeons and cli-
nicians involved in the research must possess the
knowledge, experience, skills, and technical abilities
needed to perform it safely.
3) Open display, and public and professional discussion
and evaluation: Prior to performing the procedure,
a teams’ plans should be openly publicized and dis-
cussed with professional and lay communities, thereby
allowing their input. Moreover, this input must be seri-
ously considered by the research team so that when ap-
propriate it may influence the revision of the research
proposal (see below).
4) Ethical climate of the institution: The innovation is not
being performed for purposes of institutional prestige
or professional recognition. It is rather the criteria enu-
merated here that are the truly governing ones.
and an additional 4 ethical criteria are commonly applied to
health care research.23
5) Sufficient animal research performed: Sufficient pre-
clinical research must have been done to justify moving
the research into humans. This is a specific elaboration
of Item 1.
6) Informed and willing subjects: There exist informed
subjects who, deeming the procedure beneficial, want
to undergo it and who will lose the benefits if it is post-
poned in order to wait for further developments.
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exist many other potential subjects who could, in the
future, benefit from this procedure if it proves to be
successful.
8) Regulatory approval: The procedure has been sub-
jected to the established regulatory scrutiny and re-
views, including approval by the relevant Institutional
Review Board for the Protection of Human Subjects
(IRB).
These ethical guidelines were developed to channel the
Louisville team’s research efforts and were proposed as
a framework for other teams preparing to perform facial
transplantation. If these eight criteria are satisfied, the
Louisville team submits that it is justified to perform this
experimental procedure on qualified, voluntary, and in-
formed human subjects.
Open Display and Public and Professional Discussion and
Evaluation are key components of these ethical guidelines
(Item 4 above). To achieve this, on two separate occasions,
the Louisville team published their position on face trans-
plantation in journals that solicited written critiques by
experts in related fields. These critiques were published
along side the Louisville teams’ position papers with the
teams’ response. The first of these exercised was published
in this journal.2,24e38 The second which included critiques
from the surgical teams in the UK, France, and at the Cleve-
land Clinic in the US who themselves were preparing to per-
form the procedure, was published in the American Journal
of Bioethics (AJOB). In this later case, 15 commentaries24e38
were published in AJOB, alongside the Louisville team’s
ethical guidelines and that team’s response to the commen-
taries39 (see Table 1). These commentaries comprise a com-
prehensive list of the major ethical issues being debated
today in the field of face transplantation. Below we provide
a summary these main issues.
Current standing of the key arguments
against face transplantation
Below are listed 7 of the 12 main criticisms of face trans-
plantation raised by the commentators and the Louisville
teams’ response. Many of the responses were taken from
the Louisville team’s institutional review board application
and others were newly generated in reply to the commen-
taries submitted in this valuable exercise in open discussion
and debate. The primary concerns raised by the commen-
tators included rejection rates/risks, facial tissue dona-
tion, patient compliance, exit strategy, functional
recovery, and societal and psychological implications.
Rejection rates and risks are too high
In discussing rejection, commentators focused primarily on
the rejection rates and the risks associated with rejection.
While these two topics are related, for the sake of clarity
below we will respond to each separately.
Rejection Rate: Several commentators cited rejection
rate figures published in the RCS Working Party report, stat-
ing, for example, ‘‘With facial transplantation there is an
estimated 10% chance of immediate rejection within thefirst year and a 30e50% chance of chronic rejection in
the two to five year period following transplanta-
tion.’’24,28,31,33,39,40 These figures are based on a large num-
ber of solid organ transplant outcomes, and are extremely
valuable for studying the ‘‘anti-rejection’’ effects that
different immunosuppressive drug regimens have in solid
organ transplantation. These data, in fact, were instrumen-
tal in the early planning stages of Louisville’s hand
transplant program to predict risks associated with the im-
munosuppressive drug regimens that were being considered
for use in the first hand transplant recipients. While these
statistics are of unquestioned reliability in solid organ
transplantation, they may not necessarily correlate with,
or be predictive of, the rejection of facial tissues. This is
due primarily to two main factors. First, these data are de-
rived from studies employing many different drug regimens
and not specifically those used in hand and face transplan-
tation. Second, there are substantial differences in the
composition and the antigenicity of solid organs vs. hand
and face tissues. In fact, as opposed to the 10% figure ref-
erenced by the RCS and the commentators, the one-year
post-transplant acute rejection rates in human hand trans-
plants, performed since 1998, was 65% (excluding one
transplant between identical twins). That is, 11 out of 17
hand transplants experienced a total of 26 rejection epi-
sodes with tacrolimus/MMF/corticosteroid therapy.41 But,
in spite of this relatively high incidence of acute rejection,
all episodes were reported to have been successfully re-
versed, and allograft and patient survival were 100% at
two years post transplantation. At a mean of 43 months,
graft and patient survival were 89% and 100% respectively.
Of these, there were two reported graft failures, one due
to non-compliance42 and the reason for the other failure
is unclear.41
These higher acute rejection rates in hand transplant
recipients, compared to kidney recipients receiving tacro-
limus/MMF/corticosteroid therapy, are likely the result of
the greater immunogenicity of the skin and its append-
ages.42e45 The high allograft survival rates of the hands, de-
spite relatively high acute rejection rates, may be due to
increased diagnostic sensitivity and early recognition of
subacute rejection because of the opportunity for visual
skin inspection. The importance of early diagnosis of acute
rejection has been demonstrated in clinical kidney trans-
plantation. Current methods of monitoring acute rejection
in solid organs are relatively insensitive, resulting in de-
layed anti-rejection treatment and decreased long-term al-
lograft survival. The significance of early diagnosis and
treatment of acute rejection has been demonstrated in
prospective studies of renal allograft biopsies46 in which
unrecognized acute rejection was associated with an in-
creased risk of chronic allograft nephropathy and late graft
loss.47,48 In contrast to solid organ transplants, acute rejec-
tion in hand transplants is manifested by early, visually ap-
parent cutaneous changes that have a high correlation with
histopathologic findings. Skin biopsies from co-transplanted
‘‘distant sentinel skin flaps’’ can provide valuable adjunct
information regarding acute rejection with minimal patient
morbidity.43,45
With regard to the 30e50% chronic rejection rates cited
by the RCS, these figures might be accurate for solid organ
transplants, but they do not represent what has been
358 C.S. Brown et al.observed in human hand transplants. Experience from
kidney transplantation has shown that subacute rejection
negatively affects renal allograft function.49e51 However, in
hand transplantation, this connection between subacute
and chronic rejection has not yet been established. A single
clinical and histological characterization of what was be-
lieved to be chronic (cutaneous) rejection was reported in
the recipient of the hand transplant performed in Lyon
France in 1998, but that occurred at the time the patient’s
hand was surgically removed due to non-compliance with
the anti-rejection regimen. Examination of the rejected al-
lograft demonstrated a histological picture identical to
chronic lichenoid GVHD.42,43,52 As noted above, chronic re-
jection has not been reported at a median follow up of
43 months, in the other 16 hand transplant recipients.
This low incidence of chronic rejection, even with concom-
itant high acute rejection rates41 suggests that chronic
rejection may not be as important a threat in hand as it
is in renal transplantation.53,54 Nevertheless, longer term
follow up and additional evaluations of chronic rejection
in human hand and face transplants are needed to better
define its risk and influence on long term allograft function
and survival.
Risks associated with rejection
The immunosuppression medications used to prevent hand
and facial tissue rejection are well known, having been
extensively studied in large populations of solid organ
transplant recipients and more recently in the limited
number of hand transplant recipients. Besides non-
compliance, the primary complication in the hand trans-
plant population so far has been infection. Complications
such as malignancies, cardiovascular related disease, neph-
rotoxicity, gastrointestinal adverse effects and diabetes
have not been reported41 with a post-transplant follow-up
of 43 months in human hand transplantation. This relatively
low incidence of side effects might be attributable to the
stronger general health of the hand transplant recipients
compared to kidney transplant patients, who have been
on dialysis for several years.
As it relates to people’s perception of these risks, i.e.
the amount of risk individuals are willing to accept to
receive a face transplant, the LIFT studies conducted by
the Louisville team found that individuals with facial
disfigurement (who could benefit from a face transplant),
kidney transplant recipients (who live with the risks of
immunosuppression) and healthy volunteers all would risk
the most to receive a face transplant. When provided with
a list of 20 known immunosuppression-related potential
side effects, 77% of facially disfigured respondents, 93% of
kidney transplant recipients, and 86% of the control
respondents were willing to undergo a face transplant
procedure.20
In the LIFT study respondents were also asked about
their willingness to undergo the procedure if the risk of
rejection were 50%. That figure was exceptionally high; but
since it was projected as a possibility by the RCS Working
Party, it seemed appropriate to use the figure as a worst
case scenario. When informed that the possibility of
rejecting the facial transplant within 1 year was 50%, 71%of the facially disfigured persons, 88% of organ transplant
recipients and 87% of non-affected individuals were still
willing to undergo the procedure.20 In conclusion, these
findings indicate that facially disfigured individuals and in-
dividuals who live with the risks of immunosuppression
view the risks of a face transplant as more acceptable
than do the critics of the procedure.
In summary, when comparing acute and chronic rejec-
tion rates between solid organ and hand and face trans-
plants it is essential to compare apples to apples, and this
has not yet been systematically done. Early rejection rate
data from human hand transplant recipients indicate that
these figures are very different. As it relates to risks associ-
ated with rejection, the only study performed to date that
considers the views of individuals who could benefit from
these procedures (facially disfigured) or individuals who
live with the risks of immunosuppression (kidney transplant
recipients) indicates that a significant proportion of these
individuals are willing to take this risk for the benefit of
face transplantation.
Facial tissue donation
Several commentators expressed concern with families’
willingness to donate their deceased loved one’s facial
tissues.27,32 In the words of one commentator, ‘‘Less
clear are the implications of donating a deceased loved
one’s face to a stranger.’’ The Louisville team acknowl-
edged that facial tissue donation, in comparison with tra-
ditional organ and tissue donation, posed unprecedented
complexity. To assure that donor families are treated
with the utmost sensitivity, professionals trained in work-
ing with organ donor families would interact with poten-
tial donor families. As was done in the case of hand
transplantation, the team would work closely with these
professionals to create a script for use with potential
donor families. These professionals would, of course, be
sensitive to the special concerns that families would
have for donating the facial tissues of their loved ones.
More so than in other cases of informed consent, the
care givers would need to anticipate a wide range of
questions and concerns, and special care would be taken
to guard against any kind of undue influence or manipu-
lation. Full voluntary support of donor families would
be sought; and in the event of resistance from the imme-
diate family, donation would be excluded.39
Other respondents brought up the possibility that a donor
family might request an open casket burial. With regard to
this, the family could be offered several options, including
a closed casket, cremation, or the use of a facial prosthesis,
as was done with the families of hand donors.39
Patient selection and compliance
Several commentators cited the RCS Working Party report
when voicing their concern about patient compli-
ance.27,31,33,39,40 In the words of one commentator, ‘‘The
Working Party also factored non-compliance with immuno-
suppressive medication into its risk analysis and noted
that the world’s first hand transplant resulted in graft fail-
ure due to patient-subject non-compliance’’.
Ethical considerations in face transplantation 359The recipient of the hand transplant performed in Lyon,
France, in 1998 rejected his hand after 2 years and
4 months due to his non-compliance with his immunosup-
pressive medication and had to have it removed. As rightly
pointed out in the RCS Working Party report and by several
commentators, patient compliance is a problem in organ
transplant recipients and will also be a problem in face
transplant recipients. It is the Louisville team’s view that
the failure could have been prevented by careful screening
and a thorough psychosocial and psychiatric evaluation of
this candidate. Such procedures were followed in the Louis-
ville hand transplant cases,55 and patient compliance has
been excellent. If comparably careful and thorough psycho-
social assessment of potential face transplant recipients is
practiced, similar positive outcomes can be expected.
Exit strategy
Several commentators expressed concern regarding what
would happen to the patient if the facial tissue were to
reject and had to be removed.27,31,33 In most cases, the
commentators derived this concern from a 2004 article by
Klotzko56 and the Royal College of Surgeons Working Party
report.40,57 In the words of one of the commentators: ‘‘If
the procedure should result in acute rejection then the sub-
ject may die with the entire graft sloughing off of his or her
head.’’ The Louisville team addressed this concern in the
‘‘Exit Strategy’’ section of its application to the Institu-
tional Review Board to perform a face transplant:
If the facial transplant recipient begins to exhibit signs of
severe rejection that can not be controlled or reversed with
the use of conventional immunosuppressive regimens, the
diagnosis of graft failure will be made and plans made to
surgically remove the transplanted tissue. In solid organ
transplantation (e.g. liver, heart, or lung), in which tissue
rejection results in death of the recipient, the decision to
use powerful immunosuppressive therapy is not necessarily
considered extraordinary. However, in the case of kidney,
hand and facial tissue transplantations that are instead
quality-of-life improving treatments, the use of extremely
strong medications would be considered extraordinary and
unjustifiable. Extraordinary attempts to salvage the trans-
planted facial tissue may place the recipient at substantial
risk for complications related to immunosuppressive ther-
apy, as well as the sequelae of rejecting tissues near vital
anatomic structures in the head and neck.
The Louisville team does not plan to use extraordinary
means to save the transplanted facial tissue. In the event
that the transplanted facial tissue would have to be
removed, the Louisville team plans to employ the same
conventional reconstructive techniques that were used
following the original trauma, taking measures to assure
that the patient is not worse off than he or she was before
the transplant.
Proper patient selection is critical in this regard. The
selection criteria specify that a patient should be in the
early stages of his or her reconstructive treatment. Thus, in
the event the transplanted facial tissue would have to be
removed, returning the resulting facial deformity to the
immediate post-trauma condition would be only a fewsurgeries away. In the Louisville team’s experience, con-
ventional techniques used to reconstruct this type of
complex facial deformity can require as many as 100
surgeries over periods of 15 to 20 years. Thus, selecting
a patient who is in the early stages of his or her treatment
would insure that if the patient had to return to ‘‘square
one’’ that would not be far away. If the surgical team has
to revert to conventional reconstructive methods, those
methods would be the same as the patient would have ex-
perienced without the transplant. The Louisville team’s IRB
application states:
Prior to enrollment into the facial transplantation protocol;
every effort will be made to screen potential facial trans-
plant recipients to insure that a clear understanding exists
and that no extraordinary means to reverse severe re-
jection episodes will be undertaken. Only candidates who
understand the risks of potential reconstructive procedures
and who are willing to agree to the surgical removal of the
transplanted facial tissue (once advised to do so by the
transplant team) will be eligible for transplantation.
In summary, the psychological consequences of rejec-
tion have been well considered and may become a key
factor in the patient’s willingness or resistance to pursue
extraordinary means to save the transplant. Psychological
trauma will be minimized by selecting an emotionally
resilient transplant recipient and by promptly initiating
remedial reconstructive surgery. Designed, in part, to
provide a basis for predicting the recipient’s ability to
deal with tissue rejection, the protocol reported in the
Institutional Review Board application includes an intensive
social and psychological assessment prior to surgery. The
recipient will be fully informed at the time of enrollment in
the facial transplantation selection process that the above
described scenario may occur, and that death may be
a consequence of the transplantation. Of course, no
screening process can indisputably foretell behavioral re-
sponse, and decisions made by potential recipients pre-
operatively in response to hypothetical case scenarios may
not predict the emotionally charged environment surround-
ing an actual rejection episode,39 but efforts are planned to
insure maximum patient comprehension and informed
consent.
Functional recovery
Concerns were voiced regarding the functional recovery of
transplanted facial tissues. As stated by one of the
commentators, ‘‘It is not certain that the transplant will
provide a functioning or even partially functional face.’’27
Based on previous experience of the Louisville team in reat-
taching amputated body parts, which includes transplant-
ing muscles and nerves from one part of the body to
another and transplanting hands in two recipients, it is be-
lieved that facial transplantation will be able to provide
50e80% functional recovery to the face. These estimates
are derived from the Louisville team’s extensive experience
restoring function to the face through a variety of conven-
tional microsurgical reconstructive techniques. These tech-
niques are well-established in the field and involve
transplanting muscles and nerves from other parts of the
360 C.S. Brown et al.body to the face and have been demonstrated to be very ef-
fective.58,59 Based on favorable functional outcomes
achieved by the Louisville team, as well as by other hand
transplantation teams, these same techniques will be
used and should provide similar functional recovery in
facial transplantation.
Functional recovery in the first hand transplant recipi-
ents was reported to be better than expected.14,15 This
effect is thought to be due to a collateral effect of
accelerating nerve regeneration provided by the primary
anti-rejection drug, tacrolimus, being used in these recipi-
ents.60,61 While the anticipated functional recovery is not
100%, it is expected to be superior to that achieved with
conventional reconstructive methods (skin grafts, trans-
planted autologous tissues and facial prosthetics) in the
population of patients being considered.39
Societal implications
Commentators28,35 had concerns about societal implica-
tions, which were represented in this comment: ‘‘The im-
pact of new appearance enhancing procedures on society
should not be underestimated. Experience suggests that
the publicity surrounding face transplantation will promote
unrealistic expectations of the benefits, and is likely to fuel
the notion that a good quality of life cannot be achieved by
people with disfiguring conditions.’’ The Louisville team’s
response to this concern was, ‘‘..a successful facial trans-
plant might imply that a good quality of life cannot be
achieved by people with disfiguring conditions. The public
may develop speciously unrealistic expectations for the
outcomes of such surgery, perhaps to the point of creating
an inappropriate demand for its use in less worthy cases,
such as cosmetic enhancement for the aging rich or for
criminal identity concealment. This, as well as other mis-
conceptions, can not be prevented. All that teams prepar-
ing to perform this procedure can do is provide accurate
information in order to shape public opinions in a responsi-
ble manner.’’39,62
It seems inappropriate to deprive severely disfigured
patients of the potential benefits of face transplantation
due to the possibility of public misunderstandings. If that
premise were accepted, then kidney transplantation could
be discouraged because it could cause patients to forgo
dialysis, and heart transplantation could be discouraged
because the availability of that procedure could lead
people to ignore their diet and exercise.
Psychological implications
Concerns regarding the psychological implications of face
transplantation are among the most commonly voiced.
They are also, however, the least possible to answer before
actually performing procedures and following the patients
to learn of their outcomes. The concerns of several
commentators26e28,32 are represented in the comment,
‘‘.transplantation results in a particular set of psychoso-
cial stressors, challenges and adaptive demands. These in-
clude fears relating to the viability of the transplanted
organ or limb, fear of the aftermath of rejection, the burdenof adhering to complex post-operative medical and behav-
ioral regimes and associated fears of personal responsibility
for the success or failure of the transplant, coping with the
side effects of immunosuppression, the difficulties of inte-
grating the transplant into an existing body image and iden-
tity, and emotional responses including gratitude and guilt
in relation to the donor and family. The probability is that
some of these effects will be exacerbated in the case of
face transplantation due to the significance of the face,
psychological effects of facial disfigurement and deciding
to undergo a face transplant.’’
The Louisville team concurred with this analysis and
responded that these concerns might be mitigated by
careful patient selection, ongoing monitoring, and psychi-
atric intervention, as indicated. The psychological risks
that facial transplant recipients will confront are to some
extent similar to those in solid organ transplant in which
desperation might create unrealistic hopes, followed by
disappointment that recovery is imperfect, and feelings
that the transplant violates the integrity of the self. The
scientific community’s collective experience gained in
working with solid organ recipients and in hand recipients
will be used in working with face transplant recipients. The
Louisville team plans to address possibly biased patient
evaluation of risk/benefit calculations through careful
interviewing, correction of misperceptions, and dialogical
informed consent procedures.62,63
Now that the first human face transplants
have been performed, what’s next?
The ethical questions that arise in facial transplantation are
complex and unprecedented and must include surgical,
immunological, psychological, and social dimensions be-
fore, during, and for many years after, the procedure.
Indeed as the graph in Fig. 1 demonstrates, scholarly arti-
cles on ethics almost treble those papers discussing the im-
munological and surgical aspects of face transplantation.
This trend in the literature further supports the decision
to concentrate our research efforts on the ethical and
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Figure 1 Number of publications on Ethical, Immunological
and Surgical aspects of face transplantation appearing each
year from 2002 to 2006.
Ethical considerations in face transplantation 361psychosocial dimensions of this procedure. Clearly the cen-
tral questions of face transplantation are those concerning
the ethical issues rather than surgical and immunological.
Relatively limited experience in human hand transplan-
tation has demonstrated the importance of careful psycho-
logical screening of potential candidates. The hand
transplant performed in Lyon, France, in 1998, one of
only two reported failures, was due to patient non-
compliance with the medical regimen.43,52,64e66 As dis-
cussed above, careful screening with thorough psychosocial
evaluation could have excluded this patient as a candidate
and avoided this failure.
Soon after reporting the first face transplant in Amiens,
France, newspaper reports surfaced that the patient had
a history of psychiatric problems and had resumed smoking
shortly after the procedure, which may endanger blood
flow to the transplant.67 It would be inappropriate to eval-
uate this case based on non-scientific accounts. However,
as in the first hand transplant, this case underscores the
importance of careful psychosocial evaluation in the
patient screening process. The psychological dimensions
in face transplantation will very likely be even more impor-
tant than they are in the hand. The hopes, anxieties, and
stability of all transplant recipients have always precipi-
tated ethical concerns. In the case of facial transplanta-
tion, however, the psychological and social dimensions
loom much larger because a person’s self-image, social
acceptability, and sense of normalcy as he or she subjec-
tively experiences them are at stake to a greater degree.62
Many of the ‘‘risks’’ and ‘‘benefits’’ of this new treatment
are simply unpredictable.23 The psychological dimensions
of facial transplantation cannot be learned from further
animal research or further projections of how recipients
will adapt.
To date, the ethical discussions focused on the psycho-
logical dimensions of face transplantation have been dispro-
portionately dominated by experts, without significant input
from the potential patients whom this innovative procedure
might benefit. In contrast, surveys of multiple patient
populations using the LIFT instrument have suggested high
patient perceptions of benefit and commensurate accep-
tance of risk. The results of these studies have provided
a more solid foundation upon which to introduce face
transplantation research into the clinical arena.18e20,39
In conclusion, in light of the many events that have
transpired since the Louisville team published its first
editorial in this journal two years ago, its position has
remained the same. Namely, for a select population of
severely disfigured individuals, facial transplantation, de-
spite its recognized risks, could provide a treatment option
that is definitely better than current methods. The surgical
techniques necessary to perform these procedures, while
technically demanding, are commonly performed and
readily available. Moreover, from an immunological stand-
point, the early success of hand transplants (now more than
7 years post-transplant, see Table 1), indicate that these
drugs will also be efficacious in face transplantation. While
these immunosuppressive drugs pose risks, these risks have
been extensively studied in large populations of solid-organ
transplant recipients and now hand transplant recipients.
These risks therefore are well-known and clinically
documented.As with any innovative procedure, the ethical issues
associated with its risks and benefits will always be present.
To assure that facial transplantation moves into the clinical
research phase in a thoughtful and well-planned manner,
teams proposing to perform this procedure should establish
and follow well-defined ethical guidelines. They should
contribute less to unfounded assumptions and more to
objective research which they should openly discuss and
debate with their colleagues and well as the public in
professional and public forums.
The role of clinical scientists is to gather as much
knowledge as possible about a new treatment from re-
search, clinical experience, professional and public discus-
sion, and to use this cumulative knowledge to inform his or
her patients and their families about the procedure’s
associated risks and benefits. As with all innovative medical
advances, ultimately patients must decide whether they
are to be treated. As we have stated in the previous
editorial in this journal, remaining questions will only be
answered by continuing to perform face transplant pro-
cedures and methodically following the recipients’ medical
and psychological adaptation to his or her new condition for
many years.
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